Paligenosis defines a tightly controlled program through which terminally differentiated cells re‑enter the cell cycle and ...
While many American adults are trying to reduce cholesterol levels, certain cancerous tumors have a relentless appetite for ...
Findings of a new study introduce new drug targets to selectively inhibit a key event in tumor cell progression. The study provides further insight into the control of mTORC1 activation, and ...
A phase 1, first-in-human, dose-escalation and biomarker trial of liposomal gemcitabine (FF-10832) in patients with advanced solid tumors. This is an ASCO Meeting Abstract from the 2022 ASCO Annual ...
It has long been known that the protein TOR – Target of Rapamycin – controls cell growth and is involved in the development of diseases such as cancer and diabetes. Through a collaborative effort ...
Novartis has offloaded two midphase mTORC1 inhibitors to PureTech Health. The agreement will see PureTech create a subsidiary, resTORbio, to move the assets into a phase 2b trial in diseases linked to ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results